<<
>>

1 .Sacks F. ., Svetkey L. , Vollmer W. . et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet // New Engl. J.

Med. 2001. 344. P. 3-10.

2. Higgins M., Kamel W., Garrison R. et al. Hazards of obesity the Framingham experience // Acta. Med. Scand. 1998. 723 (Suppl.). P. 23-6.

3. Mogensen . E. Hypertension & Diabetes: Vol. 3. London: Lippincott Williams & Wilkins, 2002.

4. Campbell N. R Ashley M. Carruthers S. G. et al. Lifestyle modifications to prevent and control hypertension. Recommendations on alcohol consumption // Can. Assoc. Med. J. 1999. 160 (Suppl. 9). P. 13-20.

5. Gress T. W., Nieto E /., Shahar E. et al. Hypertension and anthihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study // New Engl. J. Med. 2000. 342. P. 905-12.

6. Moser M. Clinical management of hypertension. Fourth edition. Professional Communications, Inc., 1999.

7. Oparil S Weber M. Hypertension: a companion to Brenner and Rector s The Kidney. Philadelphia: W. B. Saunders Company, 2000.

8. : . / . . . . .: , 2000.

9. Curb J. D Pressel S. L Cutler ]. A. et al. Effect of diuretic-based antihypertensive treatment on cardiovascular risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Eldery Program Cooperativa Research Group // JAMA. 1996. 276. P. 1886-92.

10. Gosse P, Sheridan D. /., Zannad E et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study // Hypertension. 2000. 18. P. 1465-75.

11. The ALLHAT Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack trial (ALLHAT).

Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlortalidone // JAMA. 2000. N 283. P. 1967-75.

12. He F. J., Markandu N. D Sangnella G. A. et al. Importance of the renin system in deter

mining blood pressure fall with salt restriction in black and white hypertensives // Hypertension. 1998. 32. P. 820-4.

13. Mar re M., Fernandez M., Garcia-Puig J. et al. Value of natrilix SR in hypertensive type 2 diabetic patients with microalbuminuria // Hypertension. 2002. 20 (Suppl. 4). P. 338-42.

14. Expert consensus document on p-adrenergic receptor blockers. The task force on Beta-Blockers of the European society of cardiology // Europ. Heart. J. 2004. 25. P. 1341-62.

15. Giugliano D., Acampora R., Marfella R. et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial // Ann. Int. Med. 1997. 126. P. 955-9.

16. Dahlof B Devereux R. B., Kjeldsen S. E. et al. Cardiovascular morbidity and mortality in the Lozartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol // Lancet. 2002. 359. P. 995-1003.

17. Jacob S Rett K Henriksen E. /. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-bloking agents? // Amer. J. Hypertens. 1998. 11. P. 1258-65.

18. de Groot A., Mathy M van Zwieten P. et al. Involvement of the betta 3 adrenoceptor in nebivolol-induced vasorelaxation in the rat aorta II J. Cardiovasc. Pharmacol. 2003. 42. P. 232-6.

19. . ., . 3. - // . 2001. 5. . 35-7.

20. . . - 2: . . . . ., 2004.

21. . ., - .

R, . . 1: // . . 2005. 6. . 43-7.

22. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 // BMJ. 1998. 317. P. 703-13.

23. . : . 4 / . . . . ̄ 2003.

24. Bakris G. L. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. A randomized controlled trial // JAMA. 2004. 292. P. 2227-36.

25. MERIT-HT Study group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomized Intervention Trial in congestive Heart failure (MERIT-HT) // Lancet. 1999. 353. P. 2001-7.

26. CIBIS-1I investigators and committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized study // Lancet. 1999. 353. P. 9-13.

27. Flather M. D., Shibata M. C., Coats A. et al. FASTTRACK Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in eldery patients with heart failure (SENIORS) // Europ. Heart. J. 2005. 26. P. 215-25.

28. The MIAMI trial research group. Metoprolol in acute myocardial infarction // New Engl. J. Med. 1985. 6. P. 199-226.

29.ISIS-1 (First International Study on Infarct Survival) Collaborative Group. Randomized trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction // Lancet. 1986. ii. P. 57-66.

30. Dargie H. /. Effect of carvedilol on outcome after myocardial infaction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial // Lancet. 2001. 357. P. 1385-90.

31. Jonas ̄ Reicher-Reiss ̈́ Boyko et al. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease // Amer.

J. Cardiol. 1996. 771. P. 1273-7.

32. Gu K., Cowie . C Harris M. I. Diabetes and decline in heart disease mortality in US adults // JAMA. 1999. 281. P. 1291-7.

33. ParvingH. H., Rossing R The use of antihypertensive agents in prevention and treatment of diabetic nephropathy// Curr. Opin. Nephrol. Hypertens. 1994. N3. P. 292-300.

34. Weidmann P Boehlen M de Courten M. Effects of different antihypertensive drugs on human proteinuria // Nephrol. Dial. Transplant. 1993. 8. P. 582-4.

35. Mulec H Johnsen S., Bjorck S. Long-term enalapril treatment in diabetic nephropathy // Kidney Int. 1994. - 45. - P. 141-4.

36.Slataper R Vicknair N.. Sadler R. et al. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease // Arch. Int. Med. 1993. 153. P. 973-80.

37. Bakris G. Copley J. B., Vicknair N. et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy// Kidney Int. 1996. 50. P. 1641-50.

38. Elving L. D Wetzels J. M. E, van Lier H. et al. Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy // Diabetologia. 1994. 37. P. 604-9.

39. Sawicki R T. For the diabetes teaching and treatment programmes working group. Stabilisation of glomerular filtration rate over 2 years in patients with diabetic nephropathy under intensified therapy regimens // Nephrol. Dial. Transplant. 1997. 12. P. 1890-9.

40. Rudberg S., Osterby R Bangstad et al. Effect of angiotensin converting enzyme inhibitor or beta blocker on glomerular structural changes in young microalbuminuric patients with type 1 (insulin-dependent) diabetes mellitus // Diabetologia. 1999. 42. P. 589-95.

41. - . : . 6 / . . . , . . . .: , 2005. . 88-97.

42. Barzilay ]. /., Davis . R., Bettencourt /. et al. Cardiovascular outcomes using doxazosin vs. Chlortalidon for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study // J. Clin. Hypertens. 2004. 6. P. 116-25.

43. - . / . . . , . . . .: , 2005. 972 .

44. Ferrari R Cucchini , Bolognesi R. et al. How do calcium antagonists differ in clinical practice? // Cardiovasc. Drugs. Ther. 1994. 8. P. 565-75.

45. Triggle D. 1 Calcium-channel antagonists: mechanisms of action, vascular selectivities, and clinical relevance // Clev. Clin. J. Med. 1992. 59. P. 617-27.

46. Purcell H., Kaddoura S. Angina, a systematic guide to investigation and treatment. London: Mosby Publishers, 2001.

47. Devis G., Somers G. E van Obberghen et al. Calcium antagonists and islet function. I. Inhibition of insulin release by verapamil // Diabetes. 1975. 24. P. 247-51.

48. Ohneda A., Kobayashi T, Nihei /. Effects of Ca antagonists, nifedipine, niludipine and verapamil on endocrine function of pancreas // Tohoku. J. Exp. Med. 1983. 140. P. 153-9.

49. Gristwood R. W., Furman B. L., Llenas /. et al. The calcium channel dloker LAS 30538, unlike nifedipine, verapamil, diltiazem of flunarizine, potently inhibits insulin secretion in-vivo in rats and dogs // J. Pharm. Pharmacol. 1992. 44. P. 851-5.

50. Kenny ]. Treating overdose with calcium channel blokers // BMJ. 1994. 308. P. 992-3.

51 .Paoletti R., Bernini E, Corsini A. et al. The antiatherosclerotic effects of calcium antagonists // J. Cardiovasc. Pharmacol. 1995. 25 (Suppl. 3). P. 6-10.

52. Furberg C. D., Psaty . M Meyer J. V. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease // Circulation. 1995. 92. P. 1326-31.

53. Pachor M., Psaty B Aldman M. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomized controlled trials // Lancet. 2000. 356. P. 1949-54.

54. Blood pressure Lowering treatment Trialists Collaboration. Effects of ACE-inhibitors, calcium antagonists, and other blood-pressure drugs: results of prospectively designed overviews of randomized trials // Lancet. 2000. 356. P. 1955-64.

55. Tuomilehto Rastenyte D Birkenhagen W. H. et al. Effect of calcium-channel blockade in older patients with diabetes and systolic hypertension. The Systolic Hypertension in Europe Trial Investigators II New Engl. J. Med. 1999. 340. P. 677-84.

56. Li L, WangJ. C., Gong L. et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension // J. Hum. Hypertens. 1998. 16. P. 1823-9.

57. Hansson L., Zanchetti A., Carruthers et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT study group // Lancet. 1998. 351. P. 1755-62.

58. Sowers /. Comorbidity of hypertension and diabetes: the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET) // Amer. J. Cardiol. 1998. 82. P. 15-9.

59. Estacio R. 0 Schrier R. W Antihypertensive therapy in type 2 diabetes: implications of the Appropriate Blood Pressure Control in Diabetes (ABCD) trial // Amer. J. Cardiol. 1998. 82. P. 9-14.

60 .Hansson L LindhoUn L. H., Ekbom T. et al. Randomised trial of old and new antihypertensive drugs in eldery patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 // Lancet. 1999. 354. P. 1751-6.

61. Brown M. J., Palmer C. R., Castaigne A. et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT) // Lancet. 2000. 356. P. 366-72.

62 .Hansson L, Hedner T, Lund-lohansen P. et al. Randomised trial of effects of calcium antagonists compared with diuretics and p-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study // Lancet. 2000. N 356. P. 359-65.

63. Pepine C. )., Hanberg E. M., Cooper-DeHoff R. M. et al. A calcium antagonist vs a non

calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The Intrenational Verapamil-Trandolapril Study (INVEST); a randomized controlled trial // JAMA. 2003. 290. P. 2805-16.

64. The ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic // JAMA. 2002. 288. P. 2981-97.

65. Hernandez R. Calcium antagonists and atherosclerosis protection in hypertension // Amer. J. Ther. 2003. 10. P. 409-14.

66. Wright I. T, Agodoa L., Contreras G. et al. Study group. Successful blood pressure control in the African-American study of kidney disease and hypertension // Arch. Int. Med. 2002. 162. P. 1636-43.

67. Herlitz ̈́ Harris ., Risler . et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros study // Nephrol. Dial. Nrans- plant. 2001. 16. P. 2158-65.

68. Agardh C. D Garcia-Puig Charbonnel B. et al. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisino- pril than by nifedipine // J. Hum. Hypertens. 1996. 10. P. 185-92.

69. Lewis E. /., Hunsicker L. G., Clarke W. R. et al. Renoprotective effect of the angiotensin- receptor antagonist in patients with nephropathy due to type 2 diabetes // New Engl. J. Med. 2001. 345. P. 851-60.

70. National Kidney Foundation. K/DOQ1 Clinical Practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. 2004.

71 .Bakris G. L, Weir M., Secic M. et al. Differential effects of calcium antagonists subclasses on markers of nephropathy progression 11 Kidney Int. 2004. 65. P. 1991-2002.

72. Zaman M. A., Oparil S Calhoun D. A. Drugs targeting the renin-angiotensin-aldosterone system // Nat. Rev. 2002. 1. P. 621-36.

73. ESC Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The task force on ACE-inhibitors of the European society of cardiology // Europ. Heart. J. 2004. 25. P. 1454-70.

74. Oksa A., Gajdos AL, Fedelesova V. et al. Effects of angiotensin-converting enzyme inhibitors on glucose and lipid metabolism in essential hypertension 11 J. Cardiovasc. Pharmacol. 1994. 23. P. 79-86.

75. Kudoh A., Matsuki A. Effect of angiotensin converting enzyme inhibitors on glucose uptake 11 Hypertension. 2000. 36. P. 239-44.

76. Galletti E, Dtrazzallo R, Capaldo B. et al. Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS) // Hypertension. 1999. N 17. P. 439-45.

77.Shiuchi T, Cui T.-X., Wu L. et al. ACE inhibitor improves insulin resistance in diabetic mouse via bradykinine and NO 11 Hypertension. 2002. 40. P. 329-33.

78. Chaturvedi N.. Fuller ]. H. ACE inhibitors and risk of hypoglycemia in people with diabetes // Diabetes, care. 1997. 20. P. 1363-7.

79. Thamer M Ray N. F., Taylor T. Association between antihypertensive drug use and hypoglycemia: a case-control study of diabetic uses of insulin or sulfonylureas // Clin. Ther. 1999. 21. P. 1387-400.

80. HOPE Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE and MICROHOPE substudy // Lancet. 2000. - 355. P. 253-9.

81. EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease : randomized , double-blind, placebo-controlled, multicentre trial (the EUROPA'study) // Lancet. 2003. 362. P. 782-788.

82. ACE-I Myocardial Infarction Collaborative group. Indications for ACE inhibitors in the early treatment of acute myovardial infarction: systematic overview of individual data from 100 000 patients in randomized trials // Circulation. 1998. 97. P. 2202-12.

83. Gruppo italiano per lo Studio della Soprawivenza nellInfarto miocardico. GISS1-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6 week mortality and ventricular function after myocardial infarction // Lancet. 1994. 343. P. 1115-22.

84. Collaborative group randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack // Lancet. 2001. 358. P. 1033-41.

85. Flather M. D Yusuf S Kober L. et al. For the ACE-inhibitor myocardial infarction col

laborative group. Long-term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients // Lancet. 2000. 355. P. 1575-81.

86. . H., . . . .: , 2000.

87. Mancini G. . /., Henry . , , et al. Angiotensin-converting enzyme inhibition with Quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND study (Trial on Reversing ENdothelial Dysfunction) // Circulation. 1996. 94. P. 258-265.

88. ODriscoll G., Green D Rankin J. et al. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus // J. Clin. Invest. 1997. 100. P. 678-684.

89. Ruggenenti R, Perna A., Gherardi G. et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial // Lancet. 1998. 352. P. 1252-6.

90. Locatelli F., Carbans l, Maschio G. et al. Long-term progression of chronic renal insufficiency in the AIPRI Extension Study // Kidney Int. 1997. 52 (Suppl. 63). P. 63-6.

91. Lewis E. J., Hunsicker L Bain R. et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group // New Engl. J. Med. 1993. 329. P. 1456-62.

92. EUCLID study group. Randomized placebo-controlled trial of lisinopril in normoten- sive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria // Lancet. 1997. 349. P. 1787-92.

93. Ruggenenti P, Fassi A., Ilieva A. et al. Preventing microalbuminuria in type 2 diabetes //

New Engl. J. Med. 2004. 351. P. 1941-51.

94. . ., . . . .: , 2000. 250 .

95. . ., . ., . III. . // . 1999. N1. . 35-9.

96. Klahr S., Levey A. S., Beck G. /. et al. The Modification of Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood pressure control on the progression of renal disease // New Engl. J. Med. 1994. 330. P. 877-84.

97. Bakris G. L Weir M. R. ACE inhibitor-assocoated elevations in serum creatinine: Is this a cause for concern? // Arch. Int. Med. 2000. 160. P. 685-93.

98. van de Ven P, Beutler /., Kaatee R. et al. Angiotensin converting enzyme inhibitor-induced renal dysfunction in atherosclerotic renovascular disease // Kidney Int. 1998. 53. P. 986-93.

99. Heeg J. E Jong P. E., van der Hem G. K. et al. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril // Kidney Int. 1989. 36. P. 272-9.

100-The EUCLID Study Co-ordinating Centre E. Differences in albumin excretion rate response to lisisnipril by ACE genotype in insulin dependent diabetes (IDDM) (abstract) // Diabetologia. 1996. 39. P. A60.

101. BiollazJ., Brunner . R., Gavras I. et al. Antihypertensive therapy with MK 421: angiotensin 11-renin relationships to evaluate efficacy of converting enzyme blocade // J. Car- diovasc. Pharmacol. 1982. 4. P. 966-72.

102. . ., . . ^ . .: , 2001. 200 .

103. Weir AL R. Angiotensin II receptor blockers: the importance of dose in cardiovascular and renal risk reduction // J. Clin. Hypertens. 2004. 6. P. 315-25.

104. Hollenberg N. K. Impact of angiotensin II on the kidney: does an angiotensin II receptor blocker make sense? // Amer. J. Kid. Dis. 2000. 36. P. SI8-23.

105. P. ., . . II // . 2002. 3. . 35-9.

106. Tuck . L., Corry D. . The metabolic effects of angiotensin receptor blockers II Curr. Hypertens. Rep. 2005. 2. P. 85-7.

107. Vitale C, Mercuro G., Castiglioni C. et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome // Cardiovasc. Diabetology. 2005. 4. P. 6-13.

108. Benson S. C., Pershadsingh H. A., Ho C.I. et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARy-modulating activity // Hypertension. 2004. 43. P. 993-1002.

109. Macdougal I. C. The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin // Nephrol. Dial. Transplant. 1999. 14. P. 1836-41.

UO.Dahlof B., Devereux R. B., Kjeldsen S. E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol // Lancet. 2002. No 359. P. 995-1003.

111. Lithell H Hansson L Skoog I. et al. The Study on Cognition and Prognosis in the El- dery (SCOPE): principal results of a randomized double-blind intervention trial // Hypertens. 2003. 21. P. 875-86.

112. Julius S., Kjeldsen S. E Weber AL et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial // Lancet. 2004. 363. P. 1198-204.

113. .. // MuKap;incnews. 2005. 1. . 1-4.

114. Dickstein ., Kjekshus ]. Effects of losartan and captopril on mortality and morbidity in high-risk patients with myocardial infarction: the OPTIMAAL randomized trial // Lancet. 2002. 360. P. 752-60.

115. Pfeffer AL A., McMurray ]. /., Velazquez E. /. et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both // New Engl. J. Med. 2003. No 349. P. 1892-906.

116. Pitt B., Segal R., Martinez F. A. et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of losartan in the eldery, ELITE) // Lancet. 1997. No 349. P. 747-52.

117. Pitt B Poole-Wihon P. A., Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial: the Losartan heart failure survival study ELITE II // Lancet. 2000. 355. P. 1582-7.

118. Maggioni A. P, Anand I., Gottlieb S. O. et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors // J. Amer. Coll. Cardiol. 2002. No 40. P. 1414-21.

119. Granger . ., VcMurray /., Yusuf S. et al. Effect of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensinconverting-enzyme inhibitors: the CHARM-Alternative study) // Lancet. 2003. 362. P. 772-6.

120. Parving H. H Lehnert H Brochner-Mortensen /. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes // New Engl. J. Med. 2001. 345. P. 870-8.

121. Andersen S., Brochner-Mortensen /., Parving H. H. et al. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria // Diabetes, care. 2003. 26. P. 3296-302.

122. Viberti G Wheeldon N. M. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus II Circulation. 2002. 106. P. 672-8.

123. Barnet A. H Bain S. C, Bouter P. et al. Angiotensin-receptor blockade versus converting enzyme inhibition in type 2 diabetes and nephropathy // New Engl. J. Med. 2004. 351. P.1952-61.

124. Brenner . M., Cooper M. E., de Zeeuw D. et al. Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy // New Engl. J. Med. 2001. 345. P. 861-9.

125. Guidelines Committee. 2003 European society of hypertension- European society of cardiology guidelines for the management of arterial hypertension II Hypertension.

2003. 21. P. 1011-53.

126. BHOK. , . (2- ). ., 2004.

127. Ernsberger , Koletsky R. /., Friedman J. . Contribution of sympathetic nervous system overactivity to cardiovascular and metabolic disease // Rev. Contem. Pharmacother. 1998. 9. P.411-28.

128. Tack C. J., Smits P, Willemsen J. J. et al. Effects of insulin on vascular tone and sympathetic nervous system in NIDDM II Diabetes. 1996. 45. P. 15-22.

129. Vollenweider P, Randin D., Tappy L. et al. Impaired insulin-induced sympathetic neural activation and vasodilation in sceletal muscle in obese humans II J. Clin. Invest. 1994. 93. P. 2365-71.

130. Ward K. D Sparrow D., Landsberg L. et al. The influence of obesity, insulin, and sympathetic nervous system activity on blood pressure // Clin. Res. 1993. 41. P. 168A.

131. MunzelM. S., Anderson E. A., Johnson A. K. et al. Mechanisms of insulin action on sympathetic nerve activity // Clin. Exp. Hypertens. 1995. 17. P. 39-50.

132. Reaven . M Lithell H., Landsberg L. Mechanism of disease: hypertension and associated metabolic abnormalities the role of insulin resistance in the sympathoadrenal system // NEJM. 1996. 334. P. 374-81.

133. Waters J., Ashford /., Jager B. et al. Trial of Physiotens in combination // J. Clin. Basic. Cardiol. 1999. 2. P. 219-24.

134.Sanjuliani A. E, Francischetti E. A., Genelhu de Abreu V. Effects of moxonidine on the sympathetic nervous system, blood pressure, plasma rennin activity, plasma aldosterone, leptin, and metabolic profile in obese hypertensive patients // J. Clin. Basic. Cardiol.

2004. 7. P. 19-25.

135.Kaan £., Zeigler D Frohly P. et al. Effect of moxonidine and agmantine on glucose metabolism // Cardiovasc. Risk. Factors. 1996. 5 (Suppl. 1). P. 331-8.

136. Bauduceau ., Mayaudon ̈́ Dupuy . Rilmenidine in the hypertensive type-2 diabetic: a controlled pilot study versus captopril // J. Cardiovasc. Risk. 2000. 7. P. 57-61.

137 .Meredith P, Reid J. Efficacy and tolerability of long-term rilmenidine treatment in hep- ertensive diabetic patients: a retrospective analysis of a general practice study // Amer. J. Cardiovasc. Drugs. 2004. 4. P. 195-200.

138-lager B Verboom C Brunner H. The clinical efficacy of moxonidine in hypertension // Rev. Contem. Pharmacother. 1998. 9. P. 463-71.

139. Trimarco B Rosiello G., Sarno D. et al. Effects of one-year treatment with rilmenidine on systemic hypertension- induced left ventricular hypertrophy in hypertensive patients // Amer. J. Cardiol. 1994. 74. P. 36A-42A.

140. Reis D. )., Regunathan S., Golanov E. V. et al. Protection of focal ischemic infarction by rilmenidine in the animal: evidence that interactions with central imidazoline receptors may be neuroprotective // Amer. J. Cardiol. 1994. 74. P. 25A-30A.

141. Pavenstadt H. New aspects concerning the role of catecholamines in the pathogenesis of glomerular diseases // Nephrol. Dial. Transplant. 1998. 13. P. 1916-9.

142. Materson B. J., Reda D. /., Cushman W. C. et al. Single-drug therapy for hypertension in men: a comparison of six antuhypertensive agents with placebo // New Engl. J. Med. 1993. 328. P. 914-21.

143. The ALLHAT Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack trial (ALLHAT) // JAMA. 2002. 288. P. 2981-97.

144. The Seventh report of the Joint National Committee on Prevention, detection, evaluation, and treatment of high blood pressure (JNC 7) // JAMA. 2003. 289. P. 2560-75.

145. ADVANCE Collaborative Group. ADVANCE action in diabetes and vascular disease: patient recrutment and characteristics of the study population at baseline II Diab. Med. 2005. 22. P. 1-7.

146. Tuomilehto ]., Rastenyte D Birkenhagen W. H. et al. Effect of calcium-channel blockade in older patients with diabetes and systolic hypertension. The Systolic Hypertension in Europe Trial Investigators // New Engl. J. Med. 1999. 340. P. 677-84.

147. Bakris G. L., Weir M. R., DeQuattro V. et al. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy // Kidney Int. 1998. 54. P. 1283-9.

148. Schneider M. et al. // Hypertension. 1996. 14. P. 669-77.

149. Menard /., Campbell D. /., Azizi M. et al. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and rennin in spontaneously hypertensive rats // Circulation. 1997. 96. P. 3072-8.

150. Webb R. L Navarrete A. E., Davis S. et al. Synergistic effects of combined converting enzyme inhibition and angiotensin II antagonism on blood pressure in conscious telemetered spontaneously hypertensive rats // Hypertension. 1998. 16. P. 843-52.

151. Cao Z., Bonnet F Davis B. et al. Additive hypotensive and antialbuminuric effects of angiotensin converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rat // Clin. Sci. 2001. 100. P. 591-9.

152 .Jacobsen P., Rossing K., Parving H.-H. Single versus dual blockade of the rennin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy // Curr. Opin. Nephrol. Hypertens. 2004. 13. P. 319-24.

153.Nakao N.. Yoshimura A. S Morta H. et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial // Lancet. 2003. 361. P. 117-24.

<< | >>
: .., ... . .: - 26 ,2006 344 .: ., .. 2006

:

  1. :
- - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - -